Brigette Roberts - 18 May 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Reporting relationship: Chief Corp. Affairs Officer, Director
Issuer ticker: QNCX
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 17:30:07 UTC
Source filing: View source filing
Reporting owner signature: /s/ Brendan Hannah, Attorney-in-Fact

Key filing fact

Brigette Roberts filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 11 Jun 2026.

Key facts

This page summarizes Brigette Roberts's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
9 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 17:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001346566 Primary reporting owner

Roberts Brigette

Relationship: Chief Corp. Affairs Officer, Director
Address: C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Signature: /s/ Brendan Hannah, Attorney-in-Fact
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +34,675
Change %
Price
Shares after: 34,675
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,675
Exercise price: $0.0900
Footnotes: F1, F2

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +228,855
Change %
Price
Shares after: 228,855
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 228,855
Exercise price: $0.0900
Footnotes: F2, F3

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +124,830
Change %
Price
Shares after: 124,830
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 124,830
Exercise price: $0.0900
Footnotes: F2, F4

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +69,350
Change %
Price
Shares after: 69,350
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 69,350
Exercise price: $0.0900
Footnotes: F2, F5

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +362,092
Change %
Price
Shares after: 362,092
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 362,092
Exercise price: $0.0900
Footnotes: F2, F6

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +133,615
Change %
Price
Shares after: 133,615
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 133,615
Exercise price: $0.0900
Footnotes: F2, F7

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,070,107
Change %
Price
Shares after: 2,070,107
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,070,107
Exercise price: $0.0900
Footnotes: F2, F8

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,837,319
Change %
Price
Shares after: 6,837,319
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,837,319
Exercise price: $0.8400
Footnotes: F2, F9

QNCX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,837,319
Change %
Price
Shares after: 6,837,319
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,837,319
Exercise price: $0.8400
Footnotes: F9, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai.

Footnote F2

Immediately exercisable.

Footnote F3

Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F4

Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F5

Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F6

Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F7

Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F8

Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.

Footnote F9

Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement.

Footnote F10

Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date.